Advisor Group Holdings, Inc. Hepion Pharmaceuticals, Inc. Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $1.06 $4,285 - $14,652	13,823 Added 41.02%	47,524 $37,000
Q4 2022 Feb 10, 2023	BUY	$0.27 - $11.9 $704 - $31,035	2,608 Added 8.39%	33,701 $10,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $10.4 $3,226 - $65,800	6,327 Added 25.55%	31,093 $16,000
Q2 2022 Aug 10, 2022	BUY	$0.57 - $1.22 $1,012 - $2,167	1,777 Added 7.73%	24,766 $14,000
Q1 2022 May 04, 2022	BUY	$0.93 - $1.29 $5,938 - $8,236	6,385 Added 38.45%	22,989 $29,000
Q3 2021 Nov 05, 2021	SELL	$1.39 - $2.1 $1,594 - $2,408	-1,147 Reduced 6.46%	16,604 $25,000
Q2 2021 Aug 02, 2021	BUY	$1.56 - $2.26 $13,481 - $19,530	8,642 Added 94.87%	17,751 $35,000
Q1 2021 May 13, 2021	BUY	$1.77 - $2.98 $9,759 - $16,431	5,514 Added 153.38%	9,109 $17,000
Q4 2020 Feb 10, 2021	BUY	$1.58 - $3.64 $1,728 - $3,982	1,094 Added 43.74%	3,595 $8,000
Q3 2020 Nov 12, 2020	BUY	$2.84 - $4.59 $4,260 - $6,885	1,500 Added 149.85%	2,501 $8,000
Q2 2020 Aug 14, 2020	BUY	$1.31 - $3.09 $1,310 - $3,090	1,000 Added 100000.0%	1,001 $3,000
Q1 2020 May 18, 2020	BUY	$1.15 - $5.74 $1 - $5	1 New	1 $0

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $57.2M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.